An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Summary

This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.

Timeline

Start

2026-04-23

Primary completion

2029-06

Completion

2029-12

Drugs

Indications